Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% – HBSS

Ionis Pharmaceuticals' stock plunged 23% on July 9, 2026, after its Phase 3 CARDIO-TTRansform trial for eplontersen failed to meet its primary efficacy endpoint. The unexpected failure wiped out $3.3 billion in market capitalization. Hagens Berman has launched an investigation into whether the company was sufficiently transparent about the trial's data and design, potentially violating federal securities laws.

07/28/2026, 12:46 PM • GlobeNewswire

Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026

Dr. Dajun Yang, Chairman and CEO of Ascentage Pharma, has been recognized in The Medicine Maker Power List 2026, ranking No. 3 in the Small Molecules category. The recognition highlights the company's achievements in advancing innovative cancer therapies, including the commercialization of olverembatinib and lisaftoclax, with multiple global Phase III clinical trials underway.

07/26/2026, 7:30 PM • GlobeNewswire

PD-1 and PD-L1 Inhibitors Clinical Trial Pipeline Analysis Demonstrates 180+ Key Companies on the Horizon Expected to Transform the Oncology Space | DelveInsight

A comprehensive analysis reveals over 180 companies developing 200+ PD-1 and PD-L1 inhibitor drugs across various clinical stages. The report highlights major pharmaceutical players advancing pipeline therapies for multiple cancer indications, with approximately 15+ drugs in late-stage development and 30+ in mid and early stages. Recent developments include FDA breakthrough designations and positive clinical trial results for combination therapies.

07/21/2026, 1:00 PM • GlobeNewswire

Clinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020-2026 | Benchmark More Than 1,800 Biopharma Deals with Various Indexes

ResearchAndMarkets.com released a comprehensive report analyzing over 1,859 clinical-stage pharmaceutical and biotechnology partnership deals announced since 2020. The report provides detailed financial terms, deal structures, contract documents, and insights into negotiation dynamics for clinical-stage drug development collaborations, serving as a benchmarking resource for biopharma dealmakers.

07/17/2026, 6:48 AM • GlobeNewswire

Bioinformatics Collaboration and Licensing Deals 2019-2026 | Compare Upfronts, Milestones, and Royalties for 1,230+ Deals

ResearchAndMarkets.com released a comprehensive report analyzing 1,230+ bioinformatics collaboration and licensing deals from 2019-2026, providing detailed benchmarking of upfronts, milestones, and royalty structures. The report serves as a reference for understanding how partnerships are structured in data-driven and platform-based transactions across the bioinformatics industry.

07/17/2026, 5:54 AM • GlobeNewswire

Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider

The global autoimmune disease therapeutics market is projected to grow from USD 80.54 billion in 2025 to USD 137.85 billion by 2035, with a CAGR of 5.52%. Growth is driven by rising prevalence of autoimmune diseases, adoption of biologics, JAK inhibitors, monoclonal antibodies, and precision medicine technologies. North America leads with 39.96% market share, while Asia-Pacific shows the fastest growth at 6.28% CAGR.

07/15/2026, 11:00 AM • GlobeNewswire

Oral Obesity Therapies Market to Reach $6.32 Billion by 2030 as Demand for GLP-1 Treatments Accelerates

The global oral obesity therapies market is projected to grow from $4.32 billion in 2026 to $6.32 billion by 2030, with a compound annual growth rate of 9.9%. The market expansion is driven by increasing demand for GLP-1 treatments, combination therapies, personalized metabolic treatments, and telehealth-enabled prescribing. Key opportunities include oral GLP-1 agonists, next-generation incretin drugs, and convenient non-injectable options for obesity management.

07/15/2026, 4:15 AM • GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

Pomerantz LLP announced investigations into potential securities fraud at AstraZeneca following the failure of its Phase-3 CARDIO-Transform trial for Wainua treatment, which caused the stock to drop 5.7%. The firm is also investigating claims against Alibaba Group and Franklin Covey Co.

07/14/2026, 4:54 PM • GlobeNewswire

AstraZeneca Selloff Looks Larger Than the Wainua Valuation Damage

AstraZeneca's stock plummeted 5.7% after its Phase 3 CARDIO-TTRansform trial for heart drug Wainua failed to meet its primary endpoint, erasing $24 billion in market value. However, analysts argue the selloff is an overcorrection, as the failed program represents only ~2% of the company's net present value. The fundamental business remains intact with strong margins, existing drug approvals unchanged, and the $80 billion 2030 revenue target untouched. The market punished the company more for a credibility crack than actual financial damage.

07/10/2026, 2:25 PM • Investing

Physicians and Patients Agree Lupus Care Is Improving, But Both Say Meaningful Gaps Remain

Despite expanding biologic adoption and evolving treatment strategies for systemic lupus erythematosus (SLE), research from Spherix Global Insights reveals substantial unmet need remains. While rheumatologists are advancing treatment strategies and increasing biologic utilization, nearly 80% of patients report moderate-to-severe disease with persistent symptoms and frequent flares. Approximately one-third of biologic-treated patients achieve only partial disease control. Recent approvals like Saphnelo® (anifrolumab) and anticipated approvals like Gazyva® (obinutuzumab) for non-renal SLE are expected to expand treatment options.

07/07/2026, 12:58 PM • GlobeNewswire

Transthyretin Amyloidosis Treatment Market Size to Reach USD 35.10 Billion by 2035, Growing at a 14.64% CAGR | SNS Insider

The transthyretin amyloidosis treatment market is projected to grow from USD 8.95 billion in 2025 to USD 35.10 billion by 2035 at a 14.64% CAGR. Growth is driven by increased ATTR-CM diagnosis rates, FDA approvals of gene-silencing therapies like vutrisiran and acoramidis, improved diagnostic imaging, and expanding pipeline therapies. North America dominates with 46% market share, while Asia Pacific is the fastest-growing region.

07/07/2026, 6:42 AM • GlobeNewswire

Acute Kidney Injury Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

The acute kidney injury (AKI) therapeutic pipeline is experiencing robust growth with 20+ pharmaceutical companies developing 25+ pipeline drugs across various clinical stages. Key players including AstraZeneca, Arch Biopartners, Akebia Therapeutics, and others are advancing promising therapies with diverse mechanisms of action. Recent developments include Phase I initiation of AKB-9090, Phase II trial preparations for LSALT peptide, and anticipated Phase III data from AstraZeneca's ARTEMIS trial in H2 2026.

06/23/2026, 1:00 PM • GlobeNewswire

Questex’s PODD, the Premier Gathering for Drug Delivery Industry Leaders, Announces the 16th Annual Conference Agenda

Questex's Fierce Life Sciences announced the agenda for the 16th annual PODD (Partnership Opportunities in Drug Delivery) Conference, scheduled for October 29-30, 2026, in Boston. The event will gather over 1,000 industry executives and features 150+ sessions with keynotes from Regeneron's Dr. George Yancopoulos and MIT's Dr. Robert Langer, covering topics including AI in drug delivery, pharma partnering strategies, and reimbursement challenges.

06/23/2026, 8:00 AM • GlobeNewswire

Cutaneous Lupus Erythematosus Market to Expand at a CAGR of 8% During the Forecast Period (2026–2036) Amid Emerging Therapies and Increasing Healthcare Investments | DelveInsight

The cutaneous lupus erythematosus (CLE) market is projected to grow at 8% CAGR through 2036, driven by emerging targeted therapies and increased disease awareness. The market was valued at USD 650 million in 2025 across seven major markets. Key pipeline drugs from major pharmaceutical companies targeting plasmacytoid dendritic cells and type I interferon pathways are expected to transform treatment options for CLE patients.

06/22/2026, 1:00 PM • GlobeNewswire

[Latest] Global GLP-1 Receptor Agonist Market Size/Share Worth USD 95.3 Billion by 2035 at a 12.1% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

The global GLP-1 receptor agonist market, valued at USD 28.7 billion in 2025, is projected to grow to USD 95.3 billion by 2035 at a 12.1% CAGR. Growth is driven by rising type 2 diabetes and obesity cases, technological innovations including oral formulations, and expanded insurance coverage. North America leads the market while Asia Pacific shows the highest growth rate.

06/16/2026, 6:30 PM • GlobeNewswire